0001628280-22-005912.txt : 20220311
0001628280-22-005912.hdr.sgml : 20220311
20220311162249
ACCESSION NUMBER: 0001628280-22-005912
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220311
FILED AS OF DATE: 20220311
DATE AS OF CHANGE: 20220311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NEIL GARRY ARTHUR
CENTRAL INDEX KEY: 0001586785
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31161
FILM NUMBER: 22733426
MAIL ADDRESS:
STREET 1: 555 CALIFORNIA STREET
STREET 2: SUITE 365
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001080709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 232908305
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-453-7200
MAIL ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
wf-form4_164703375138640.xml
FORM 4
X0306
4
2022-03-11
1
0001080709
ARENA PHARMACEUTICALS INC
ARNA
0001586785
NEIL GARRY ARTHUR
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2022-03-11
4
J
0
8150
D
3067
D
Common Stock
2022-03-11
4
J
0
3067
D
0
D
Stock Option (right to buy)
14.6
2022-03-11
4
D
0
7500
D
Common Stock
7500.0
0
D
Stock Option (right to buy)
14.6
2022-03-11
4
D
0
4167
D
Common Stock
4167.0
0
D
Stock Option (right to buy)
13.6
2022-03-11
4
D
0
15000
D
Common Stock
15000.0
0
D
Stock Option (right to buy)
49.17
2022-03-11
4
D
0
5000
D
Common Stock
5000.0
0
D
Stock Option (right to buy)
56.5
2022-03-11
4
D
0
5000
D
Common Stock
5000.0
0
D
Stock Option (right to buy)
61.31
2022-03-11
4
D
0
5000
D
Common Stock
5000.0
0
D
Stock Option (right to buy)
65.19
2022-03-11
4
D
0
7202
D
Common Stock
7202.0
0
D
Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes.
Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes.
Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
/s/ Andrew J. Cronauer, as Attorney-in-Fact
2022-03-11